New antibody combo targets Hard-to-Treat cancers

NCT ID NCT05753722

Recruiting now Disease control Sponsor: Incendia Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug called PRTH-101, alone or with an existing immunotherapy (pembrolizumab), in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The study will enroll about 270 people and focus on safety, dosing, and how the drug moves through the body. It is not yet known if PRTH-101 will shrink tumors or improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PRTH-101 (a lab-made antibody) and pembrolizumab (an immunotherapy drug)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial, so the main goal is safety, not effectiveness. The drug may not work or could cause serious side effects. Only a small number of people will be tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR METASTATIC SOLID TUMORS NON-SMALL CELL LUNG CANCER NSCLC

Contacts and locations

Locations

Honor Health Research Institute
RECRUITING

Scottsdale, Arizona, 85258, United States
Mass General Cancer Center
RECRUITING

Boston, Massachusetts, 02114, United States
NEXT Houston
RECRUITING

Houston, Texas, 77054, United States
NEXT Oncology
RECRUITING

San Antonio, Texas, 78229, United States
Next Oncology
RECRUITING

Irving, Texas, 75039, United States
Next Oncology
RECRUITING

Fairfax, Virginia, 22031, United States
Providence Cancer Institute Franz Clinic
RECRUITING

Portland, Oregon, 97213, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
University of Pittsburgh Medical Center Hillman Cancer Center
COMPLETED

Pittsburgh, Pennsylvania, 15232, United States
Vanderbilt-Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 27232, United States
Yale Cancer Center
RECRUITING

New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.